Hengrui makes headway with novel drugs but investors bide their time
A cancer drug developed by the Chinese firm has entered the European regulatory process and Novo Nordisk has bought rights to a potential weight-loss therapy Key Takeaways: Hengrui Pharma’s cancer…
Medtide launches IPO to bulk up its weight-loss business
The pharmaceutical services firm wants to expand production of peptides used in anti-obesity drugs, but it faces fierce competition and other business risks Key Takeaways: The global market for developing…
Will Trump’s drug order put the brakes on China’s overseas pharma drive?
The U.S. president has promised to reduce prescription drug prices by 30% to 80% for Americans, insisting they are entitled to prices paid in other developed countries Key Takeaways: Pharma…
Innogen Pharma jostles for a slice of the weight-loss market
The developer of diabetes and anti-obesity drugs has applied for a Hong Kong IPO as it prepares for battle in a crowded arena Key Takeaways: Innogen is expected to launch…
PegBio aims to bulk up its finances to deliver weight-loss drugs
The Chinese developer of anti-obesity and diabetes drugs has applied for a Hong Kong listing to fund its commercial plans, but will face strong competition Key Takeaways: The company’s core…
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand Key Takeaways: Ascletis Pharma has shifted to weight…
Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
The developer of treatments for cancer and bone fractures is branching out into the weight-loss market, but faces strong competition there Key Takeaways: At present, Jiuyuan Gene relies heavily on…
Recent Articles
RELATED ARTICLES
-
Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
-
Can a novel sleeping pill help Jingxin shed its generic label?
002020.SHE
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
-
Salubris refiles for Hong Kong IPO as generics lose steam
002294.SHE
-
Drug setback leaves Ascletis with an all-in bet on weight loss
1672.HK
-
Then there were two: BeOne moves beyond single-blockbuster dependence
6160.HK688235.SHGONC.US
